Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal Post author:Sam Post published:December 26, 2017 Post category:BioPharma Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace You Might Also Like Vertex Quietly Terminates a Small Phase II CF Trial September 11, 2017 Sanofi Appoints Executive Vice President Diabetes & Cardiovascular October 1, 2017 FDA Calls Novartis' Melanoma Combo Drug a Breakthrough October 22, 2017
